Thank you. Operator.
And welcome to the presentation of Bactiguard's Q1 2025 report. Our CFO, Patrick Bach, and I will go through the presentation together.
And as usual, we will have a Q&A session towards the end.
I will begin by sharing some brief comments on the first quarter results, and Patrick will go through the financials in more detail later in the presentation. Firstly, we are very pleased to again report both continued profitability and revenue growth. We delivered an EBITDA of 9.4 million SEK and revenues of 62.7 million SEK, which is an increase of almost 7% compared to Q1 last year. Increased license revenues stem primarily from our strengthened collaboration with medtech company BD. A prime example of a mutually beneficial relationship that is driving growth for both parties.
I will provide a more detailed update regarding the BD partnership shortly.
Another highlight for Q1 comes from our wound management portfolio.
Revenues increased by more than 50%, driven by sales of our Hydrocyn aqua line of products.
We now have four quarters in a row with positive financial development, demonstrating that we are consistently doing what we said we would do and delivering on our promise of profitability. Following the financial turnaround and strategic shift from 2024 as a major event during the quarter, in early March, we announced our updated strategic and financial targets to be achieved by the year-end 2030, and I will take this opportunity to repeat them.
First, more than ten application areas in exclusivity or licensed partnerships.
Second, revenues of at least 600 million SEK and third, an EBITDA of at least 200 million SEK in connection with the targets.
We also revised our focus on therapeutic areas for the licensed business, and I will also come back to this in a couple of slides. As I noted in the CEO statement in the report, we have established a solid foundation to achieve the updated strategic and financial targets, while at the same time maintaining a clear focus on growth and profitability.
In short, Bactiguard has had a great start to 2025.
Before we go into more detail on the quarter itself, I wanted to reflect on the reason we are here to begin with. Infection prevention continues to be a critical global medical need, and the demand for effective solutions is more pressing than ever due to the challenges faced by healthcare providers. Healthcare-associated infections are very common, with 1 in 10 patients worldwide affected by HAIs. 40 to 60% of all HAIs are caused by medical devices, and the costs associated with HAIs are significant, related to longer hospitalizations and the additional need for treatments. HAIs, however, can be significantly reduced through proactive infection prevention strategies, and it is estimated that up to 50% of all HAIs are preventable. According to the World Health Organization, proactive infection prevention is a core pillar to avoiding AMR while also being cost-effective.
Bactiguard's infection prevention technology is a real solution to this challenge with its ultra-thin layer of noble metals: gold, silver, and palladium, which has been demonstrated to work on multiple types of materials and devices and in different clinical settings. Our technology has amassed a wealth of real-world evidence of its safety and efficacy in reducing medical device-related infections. This technology platform endures beyond today's market volatility.
Through partnerships with leading medtech companies, we enable differentiated medical devices to reach a broad global market. With infection prevention as our overarching theme.
Our focus within the license business is to continue to strengthen existing partnerships, such as our excellent collaboration with BD, while simultaneously seeking new business relationships in additional application areas. Another pillar of our strategy is the continuous enhancement of our knowledge and specialist expertise.
To further reinforce collaborations within our current partnerships, we will continue investing in critical competency areas such as research and development, medical, and regulatory. These investments are also essential to drive new business and partnership development.
Our ambition is to always be the best partner to our partners by aligning with positive outcomes for them. We similarly achieve positive outcomes for Bactiguard Holding AB within our Wound Management portfolio.
The focus is on continuing profitable growth and expansion into new markets.
The need for infection prevention that I highlighted earlier spans our strategic therapeutic areas and presents significant opportunities for ZNN Bactiguard.
In the left column, we show the prioritized therapeutic areas for the licensed business, which were revised in connection with the 2030 targets.
Orthopedics, Cardiology, Neurology. Urology and vascular access.
Each of these includes relevant application areas where our infection prevention solutions can play an important role in addressing the unmet need associated with medical device-related infections, and where there is commercial and realizable potential for Zimmer Biomet and Bactiguard. Orthopedics holds great potential in an addressable market of almost $40 billion, with a wide array of relevant application areas covering implants throughout the body.
This area also has a significant number of procedures performed and a correspondingly high number of device-related infections. Rates of infection can also be very significant, especially in fracture and trauma-associated procedures, where these rates can reach up to 40%.
In addition to our existing relationship with Zimmer Biomet in trauma, we are actively seeking new licensed partners for other orthopedic categories.
Cardiology and neurology are newer therapeutic areas for Bactiguard, but present significant potential both in terms of market sizes of ten billion and nine billion USD, respectively, as well as meaningful infection rates associated with implantable devices across various application areas. These devices include materials that Bactiguard Holding AB coated, and we have expertise in the area, including through our board members, Anna Martling, Professor of Surgery at Karolinska Institutet, and Doctor Rick Kuntz, former Chief Medical and Scientific Officer at Medtronic and an expert in cardiology and clinical research within urology. We have our well-established partnerships for Foley catheters, but we see continued growth potential in this therapeutic area.
In other applications. Beyond the Foley's, vascular access is an area where Bactiguard has had its own approved CVC product in the portfolio, demonstrating our ability to coat and to bring to market relevant products in this category. Across the top of the chart are our partnership journey stages, against which we will communicate progress in our business development activities. In the far right column, we have our existing relationships at the license partnership stage with products on the market in the relevant therapeutic area.
We will continue to communicate both license and exclusivity partnerships to the market with our partner company and the application area included in the collaboration, along with any other material aspects of the collaboration. Our activities at the two earlier phases of application development and material transfer will be disclosed by therapeutic area, and we will not disclose more details around the companies or indeed the number of active collaborations. The specific timeline from early feasibility under an MTA through to a marketed product can vary based on device class, desired product claims, and the associated time to deliver the data demonstrating efficacy and safety. The partnership journey from early-stage testing to commercialization can take, on average, 5 to 7 years, as we have communicated previously along the journey.
Partners can enter exclusivity with Bactiguard for a particular area, and this is the point at which we will announce who the partner is and what we are working on together. By the time of market approval and launch, we will update the status of our specific partnerships on a regular basis, as we do with our existing license partnerships. In addition to these licensed partnerships shown here, Bactiguard is currently working in early feasibility and performance testing under material transfer agreements within the category of vascular access, as well as in categories that are outside of the highlighted strategic therapeutic areas. While these named therapeutic areas remain the focus of our proactive efforts, we will work on selected opportunities outside of these therapeutic areas where we and our potential partners believe there is a clear need for infection prevention and see potential in our technology.
This snapshot will be presented in connection with our quarterly reports or when we announce new exclusivity or license partnerships.
Now let's take a closer look at our partnership, starting with the global medtech company BD.
During the first quarter, we continued our active collaboration spanning the entire value chain, from technology licensing to go-to-market strategies. This is really a model partnership built on newly fully aligned incentives, coupled with mutual trust and respect, thus enabling win-win outcomes for both collaboration partners. One example from this past March is when Bactiguard Holding AB and BD attended an important healthcare conference in India. CRITICARE 2025 brings together intensivists, anesthesiologists, emergency physicians, and other healthcare professionals dedicated to critical care in India.
Addressing such a broad audience together marked an important step in informing local stakeholders and key opinion leaders that BD is taking over the sales and distribution of Bactiguard-coated Foley catheters in India.
Following BD's successful market registration late last year, BD is also relaunching the Bactiguard Covid Foley catheters Bardex IC in the US, and a new product website is already available for viewing.
In addition, we continue our joint work on the market registrations required to enable BD launches in new markets, like the one achieved in India.
There is clear demand across markets, and we receive many inquiries from both healthcare professionals and patients about when the Catheter products will be transferred and available in their respective markets. That level of engagement from the healthcare community is the strongest endorsement our technology can receive.
Within the Trauma Partnership collaboration.
Zimmer Biomet has focused on the commercialization of the ZNN Bactiguard-coated orthopedic trauma implant. Now, in existing markets during the first quarter, we also continued to work actively on the processes to retain regulatory approval under MDR in Europe and thus required to enable continued commercialization. The post-market clinical trials in Europe on Bactiguard Holding AB continue and will gather data on infection rates, safety, and clinical outcomes.
Both the MDR registration and clinical trial work are expected to continue for the next couple of years.
Our wound management portfolio had a really strong first quarter with a revenue increase of more than 50%. The increase was fueled by a significant rise in sales of the Hydrocyn aqua branded range of products.
In April, we hosted a panel with international wound care experts and specialists to discuss Clean to Heal, a thought leadership concept emphasizing the importance of effective debridement and cleansing to promote healing.
The conversation resulted in a consensus report published in Wounds International, a peer-reviewed journal with a long-standing reputation for advancing global wound care through evidence-based insights and expert-led clinical guidance.
During the quarter, our Malaysian production site was also formally certified ISO 14001 from the British Standards Institution. Manifesting our commitment to high-quality and responsible manufacturing and production processes.
Reiterating the strategy for Wound Management, we remain focused on stable profitability and expansion into new markets, primarily in Asia.
And now I will hand over to Patrick to review our Q1 financial outcomes in more detail.